XML 52 R33.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Sales revenue, net | Incyte Corporation (Incyte) |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 53.00% | 26.00% | 31.00%
Sales revenue, net | McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 12.00% |  |
Sales revenue, net | ASD Healthcare and Oncology Supply |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 10.00% |  |
Sales revenue, net | Provention Bio, Inc. (Provention) |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 10.00% | 43.00% |
Sales revenue, net | Zai Lab Limited (Zai Lab) |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable |  | 15.00% | 30.00%
Sales revenue, net | I-Mab Biopharma |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable |  |  | 16.00%
Accounts receivable | Incyte Corporation (Incyte) |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 25.00% |  |
Accounts receivable | McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 16.00% |  |
Accounts receivable | Cardinal Health |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 18.00% |  |
Accounts receivable | ASD Healthcare and Oncology Supply |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 15.00% |  |
Accounts receivable | Provention Bio, Inc. (Provention) |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable |  | 84.00% |
Accounts receivable | Zai Lab |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 12.00% |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2 + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_IncyteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_ProventionBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_IMabBiopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_CardinalHealthIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_ZaiLabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |